After Hours
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility.
Stocks Info
CYTK belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. The current market capitalization of Cytokinetics Inc is $5.36B. A total of 1.78 million shares were traded on the day, compared to an average of 1.39M shares.
In the most recent transaction, Malik Fady Ibraham sold 2,000 shares of CYTK for 45.98 per share on Feb 18 ’25. After the transaction, the EVP Research & Development now owns 116,071 company shares. In a previous transaction on Feb 04 ’25, Malik Fady Ibraham sold 2,000 shares at 48.06 per share. CYTK shares that EVP Research & Development owns now total 116,071.
Among the insiders who sold shares, Malik Fady Ibraham disposed of 2,000 shares on Jan 21 ’25 at a per-share price of $45.92. This resulted in the EVP Research & Development holding 116,071 shares of CYTK after the transaction. In another insider transaction, Malik Fady Ibraham sold 2,000 shares at $49.32 per share on Jan 07 ’25. Company shares held by the EVP Research & Development now total 116,071.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. In terms of 52-week highs and lows, CYTK has a high of $81.36 and a low of $40.53.
As of this writing, CYTK has an earnings estimate of -$1.17 per share for the current quarter. EPS was calculated based on a consensus of 16.0 estimates, with a high estimate of -$0.3 per share and a lower estimate of -$1.52.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. CYTK’s latest balance sheet shows that the firm has $471.64M in Cash & Short Term Investments as of fiscal 2021. There were $269.93M in debt and $71.86M in liabilities at the time. Its Book Value Per Share was -$0.12, while its Total Shareholder’s Equity was $243.86M.
Analysts Opinion
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for CYTK is Buy with a score of 4.57.
